Acknowledged examples include sparing of adjuvant therapy in patients with stage II colon cancer showing microsatellite instability (MSI) [7,8], effectiveness of biological therapy according to RAS-pathway status in advanced disease [9] prescription of immune therapy in patients with advanced MSI colon cancer, and possibly the responsiveness of the same tumors to kinase inhibitors if showing hypermethylation of MLH1 promoter and RAS/BRAF wild-type [10]. This evidence concerns the gene MLH1 and malignant colon neoplasm.